Evidence map›Paper›PMID 27171412›Full record

ArticlePloS one2016

A Novel Method for Gene-Specific Enhancement of Protein Translation by Targeting 5'UTRs of Selected Tumor Suppressors.

Adam Master, Anna Wójcicka, Kamilla Giżewska, Piotr Popławski, Graham R Williams, Alicja Nauman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Antisense oligonucleotide-mediated upregulation ofMolecular therapy. Nucleic acids · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Adam MasterThe Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, ul. Marymoncka 99/103, 01-813, Warsaw, Poland.
Anna WójcickaThe Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, ul. Marymoncka 99/103, 01-813, Warsaw, Poland.
Kamilla GiżewskaBioTe21, Laboratory of Molecular Medical Biology, ul. Krolowej Jadwigi 33/3b, 30-209, Cracow, Poland.
Piotr PopławskiThe Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, ul. Marymoncka 99/103, 01-813, Warsaw, Poland.
Graham R WilliamsMolecular Endocrinology Group, Department of Medicine, Imperial College London, Hammersmith Campus, London, W12 0NN, United Kingdom.
Alicja NaumanThe Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, ul. Marymoncka 99/103, 01-813, Warsaw, Poland.
Postgraduate School of Molecular Medicine · PLHammersmith Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranslational control is a mechanism of protein synthesis regulation emerging as an important target for new therapeutics. Naturally occurring microRNAs and synthetic small inhibitory RNAs (siRNAs) are the most recognized regulatory molecules acting via RNA interference. Surprisingly, recent studies have shown that interfering RNAs may also activate gene transcription via the newly discovered phenomenon of small RNA-induced gene activation (RNAa). Thus far, the small activating RNAs (saRNAs) have only been demonstrated as promoter-specific transcriptional activators.

findingsWe demonstrate that oligonucleotide-based trans-acting factors can also specifically enhance gene expression at the level of protein translation by acting at sequence-specific targets within the messenger RNA 5'-untranslated region (5'UTR). We designed a set of short synthetic oligonucleotides (dGoligos), specifically targeting alternatively spliced 5'UTRs in transcripts expressed from the THRB and CDKN2A suppressor genes. The in vitro translation efficiency of reporter constructs containing alternative TRβ1 5'UTRs was increased by up to more than 55-fold following exposure to specific dGoligos. Moreover, we found that the most folded 5'UTR has higher translational regulatory potential when compared to the weakly folded TRβ1 variant. This suggests such a strategy may be especially applied to enhance translation from relatively inactive transcripts containing long 5'UTRs of complex structure. SIGNIFICANCE: This report represents the first method for gene-specific translation enhancement using selective trans-acting factors designed to target specific 5'UTR cis-acting elements. This simple strategy may be developed further to complement other available methods for gene expression regulation including gene silencing. The dGoligo-mediated translation-enhancing approach has the potential to be transferred to increase the translation efficiency of any suitable target gene and may have future application in gene therapy strategies to enhance expression of proteins including tumor suppressors.

Indexed as

Genes, Tumor SuppressorGenetic Techniques5' Untranslated RegionsBase SequenceCell Line, TumorCyclin-Dependent Kinase Inhibitor p16Gene Expression RegulationHumansNucleic Acid ConformationProtein BiosynthesisReceptors, Thyroid HormoneRegulatory Sequences, Nucleic AcidThermodynamics5' Untranslated RegionsCyclin-Dependent Kinase Inhibitor p16Receptors, Thyroid Hormone

Identifiers

PMID27171412
PMCPMC4865139
OpenAlexW2380288276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.